Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis.
Helena C BartelsAilin C RogersJames PostleConor ShieldsJurgen MulsowJohn ConneelyDonal J BrennanPublished in: Pleura and peritoneum (2019)
In conclusion, secondary CRS for recurrent ovarian cancer is a safe and feasible option in carefully pre-selected patients with comparable morbidity to primary CRS.